| Item Type | Name |
|
Academic Article
|
Evaluation of platelet function by flow cytometry.
|
|
Academic Article
|
Application of flow cytometry to platelet disorders.
|
|
Academic Article
|
Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity.
|
|
Academic Article
|
Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation.
|
|
Academic Article
|
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'.
|
|
Academic Article
|
Cystic fibrosis heterozygotes do not have increased platelet activation.
|
|
Academic Article
|
Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models.
|
|
Academic Article
|
The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.
|
|
Academic Article
|
Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation.
|
|
Academic Article
|
Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction.
|
|
Academic Article
|
Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity.
|
|
Academic Article
|
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
|
|
Academic Article
|
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
|
|
Academic Article
|
Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation.
|
|
Academic Article
|
Arg-Gly-Asp-dependent occupancy of GPIIb/IIIa by applaggin: evidence for internalization and cycling of a platelet integrin.
|
|
Academic Article
|
Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
|
|
Academic Article
|
Platelet activation in cystic fibrosis.
|
|
Academic Article
|
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
|
|
Academic Article
|
Indices of platelet activation and the stability of coronary artery disease.
|
|
Academic Article
|
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
|
|
Academic Article
|
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
|
|
Academic Article
|
Immunophenotypic analysis of platelets.
|
|
Academic Article
|
Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests.
|
|
Academic Article
|
Platelet reactivity with prolonged aspirin treatment--steady going at 2 year.
|
|
Academic Article
|
The Platelet Activity After Clopidogrel Termination (PACT) study.
|
|
Academic Article
|
The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea.
|
|
Academic Article
|
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.
|
|
Academic Article
|
The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors.
|
|
Academic Article
|
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.
|
|
Academic Article
|
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.
|
|
Academic Article
|
P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
|
|
Academic Article
|
Prevention of experimental carotid artery thrombosis by applaggin.
|
|
Concept
|
Platelet Activation
|
|
Academic Article
|
Platelet activation and inhibition in sickle cell disease (pains) study.
|
|
Academic Article
|
A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.
|
|
Academic Article
|
Platelet activation using electric pulse stimulation: growth factor profile and clinical implications.
|
|
Academic Article
|
The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
|
|
Academic Article
|
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.
|
|
Academic Article
|
Platelet-rich plasma stimulated by pulse electric fields: Platelet activation, procoagulant markers, growth factor release and cell proliferation.
|
|
Academic Article
|
Platelet Physiology.
|
|
Academic Article
|
In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization.
|
|
Academic Article
|
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
|
|
Academic Article
|
Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich Plasma.
|
|
Academic Article
|
Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology.
|
|
Academic Article
|
Publisher Correction: GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation.
|
|
Academic Article
|
Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease.
|
|
Academic Article
|
GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation.
|
|
Academic Article
|
Using flow cytometry to monitor glycoprotein IIb-IIIa activation.
|
|
Academic Article
|
Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
|
|
Academic Article
|
Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting.
|
|
Academic Article
|
Biomarkers of platelet activation and cardiovascular risk in the DAPT trial.
|
|
Academic Article
|
Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency.
|
|
Academic Article
|
Platelet mass cytometry: Optimization of sample, reagent, and analysis parameters.
|
|
Academic Article
|
Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin.
|
|
Academic Article
|
Immunophenotypic Analysis of Platelets by Flow Cytometry.
|
|
Academic Article
|
Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher Disease.
|
|
Academic Article
|
Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization.
|
|
Academic Article
|
Comprehensive phenotyping of human platelets by single-cell cytometry.
|
|
Academic Article
|
OMIP-097: High-parameter phenotyping of human platelets by spectral flow cytometry.
|
|
Academic Article
|
Platelet Physiology.
|
|
Academic Article
|
Flow Cytometry and Platelets.
|